Loading
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Previous close
$3.56
−$0.14 · -3.78%
Pre-market
$3.45
−$0.11 · -3.09%
Sep 9, 8:22 AM ET
Regular session · ET · Market data may be delayed.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $3.56
52-week range
Current $3.56
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
30
Expensive
Sentiment
60
Mixed
Risk
75
High Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $3.56
52-week range
Current $3.56
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.63M USD | 2.98M USD | — | — | — |
| Cost of goods sold | 7.32M USD | — | — | — | — |
| Gross profit | −2.69M USD | 2.98M USD | — | — | — |
| Research and development | 160.64M USD | 155.29M USD | 147.91M USD | 86.73M USD | 70.55M USD |
| Selling, general, and administrative | 52.35M USD | 50.16M USD | 43.39M USD | 29.82M USD | 13.92M USD |
| Operating expenses | 205.66M USD | 205.45M USD | 204.79M USD | 116.54M USD | 84.47M USD |
| Interest income | 4.15M USD | 3.52M USD | — | — | — |
| Depreciation and amortization | 5.38M USD | 6.13M USD | 4.65M USD | 2.22M USD | 568K USD |
| Operating income | −208.35M USD | −202.47M USD | −204.79M USD | −116.54M USD | −84.47M USD |
| Net income | −201.14M USD | −195.88M USD | −198.13M USD | −121.82M USD | −165.37M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.50
110.67% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Mar 22, 2018 | $0.006Quarterly | — | Mar 29, 2018 |
Ex-dividend Mar 22, 2018
$0.006
Quarterly
Payment Mar 29, 2018
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
